Heart Failure with Preserved Ejection Fraction: Uncertainties and Dilemmas
Population
Patients with heart failure with preserved ejection fraction (HFpEF)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Diagnostic gaps in HFpEF limit targeted care; leaves open validated criteria to test disease-modifying therapies.
Key Points
- To explore the uncertainties and challenges surrounding heart failure with preserved ejection fraction (HFpEF), including diagnostic criteria and treatment options.
- Expert meeting held at the University of Ferrara to discuss HFpEF.
- Analysis of current diagnostic criteria, risk factors, and treatment options.
- Review of the heterogeneity in HFpEF's aetiology and pathophysiology.
- Evidence suggests no solid treatment currently alters the natural history of HFpEF.
- About 30% of patients with acute congestion requiring hospitalization die within 1 year; two-thirds from cardiovascular causes.
- Chronic stable patients show a significantly better prognosis.
Structured PICO
P
Population
Patients with heart failure with preserved ejection fraction (HFpEF)
This expert review highlights the lack of clear diagnostic criteria and proven disease-modifying therapies for HFpEF, emphasizing the need for better disease characterization.
Cite This Study
Ferrari et al. (2015) studied this question.